SSA
FULC icon

Schonfeld Strategic Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,791
Closed -$190K – 2378
2025
Q4 		$190K Sell
16,791
-349,512
-95% -$3.56M ﹤0.01% 1726
2025
Q3 		$3.37M Buy
366,303
+161,903
+79% +$1.17M 0.02% 777
2025
Q2 		$1.41M Buy
+204,400
New +$1.09M 0.01% 1163
2024
Q2 		– Sell
-29,169
Closed -$275K – 2296
2024
Q1 		$275K Sell
29,169
-403,364
-93% -$3.6M ﹤0.01% 1682
2023
Q4 		$2.92M Buy
+432,533
New +$1.92M 0.02% 678
2023
Q1 		– Sell
-106,600
Closed -$776K – 2273
2022
Q4 		$776K Buy
106,600
+40,000
+60% +$261K 0.01% 1283
2022
Q3 		$539K Buy
66,600
+36,000
+118% +$258K ﹤0.01% 1697
2022
Q2 		$150K Sell
30,600
-9,000
-23% -$88K ﹤0.01% 2007
2022
Q1 		$936K Buy
39,600
+4,100
+12% +$58K 0.01% 1028
2021
Q4 		$628K Sell
35,500
-46,600
-57% -$923K 0.01% 1152
2021
Q3 		$2.32M Buy
+82,100
New +$1.56M 0.02% 667

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Schonfeld Strategic Advisors's FULC Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 16,791 shares — an estimated $190K sold.

Schonfeld Strategic Advisors first reported a position in FULC in Q3 2021 and held it in 11 quarters. The position peaked at $3.37M in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,791 Fulcrum Therapeutics shares in Q1 2026, an estimated $190K.
  • Schonfeld Strategic Advisors first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 11 quarters.
  • Schonfeld Strategic Advisors's Fulcrum Therapeutics position peaked at $3.37M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.